Pharma BD Deal Intelligence

Synthego Corporation / AstraZeneca PLC

2025 · Licensing/Option · Complete

Synthego signed a strategic licensing agreement with AstraZeneca granting Synthego a global license to manufacture and distribute AstraZeneca's engineered CRISPR nuclease eSpOT-ON (published as engineered ePsCas9) to the worldwide research community, offered as recombinant protein and mRNA. Synthego also received exclusive commercialization rights, including the right to sublicense the nuclease for therapeutic and commercial use, and will pair it with its gRNA offering. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals